Bosentan alleviates the pro-fibrotic phenotype of lung scleroderma fibroblasts: Implications for treatment of scleroderma.
Egile Nagusiak: | Leask, A, Xu, S, Renzoni, E, Bou-Gharios, G, du Bois, R, Abraham, D, Black, C |
---|---|
Formatua: | Conference item |
Argitaratua: |
2005
|
Antzeko izenburuak
-
Bosentan attenuates the profibrotic gene expression profile of lung fibroblasts in scleroderma
nork: Shiwen, X, et al.
Argitaratua: (2006) -
Effects of bosentan on collagen type I synthesis on in vitro culture of scleroderma skin fibroblasts
nork: S. Soldano, et al.
Argitaratua: (2011-01-01) -
Successful Treatment with Bosentan of Lower Extremity Ulcers in a Scleroderma Patient
nork: Alix Naert, et al.
Argitaratua: (2013-01-01) -
CTGF overexpressing mice: a model for human scleroderma
nork: Sonnylal, S, et al.
Argitaratua: (2006) -
Bosentan Does Not Affect Renal Resistive Index in Scleroderma/Systemic Sclerosis Patients
nork: Emma Di Poi, et al.
Argitaratua: (2023-11-01)